{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:34:10Z","timestamp":1793450050581,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:00:00Z","timestamp":1793404800000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ard.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:14:22Z","timestamp":1791260062000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review"],"prefix":"10.1016","author":[{"given":"Josef","family":"Smolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baran","family":"Ufuktepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-201X","authenticated-orcid":false,"given":"Immaculate","family":"Nevis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy M.","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.08.009_bib0001","unstructured":"Mayo Clinic. Rheumatoid arthritis. 2023 [cited 2025 Feb 23]. Available from:https:\/\/www.mayoclinic.org\/diseases-conditions\/rheumatoid-arthritis\/symptoms-causes\/syc-20353648"},{"issue":"1","key":"10.1016\/j.ard.2026.08.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003975","article-title":"Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study","volume":"10","author":"L\u00f3pez-Medina","year":"2024","journal-title":"RMD open."},{"issue":"3","key":"10.1016\/j.ard.2026.08.009_bib0003","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jcot.2019.03.007","article-title":"Rheumatoid factor and rheumatoid arthritis","volume":"10","author":"Handa","year":"2019","journal-title":"J Clin Orthop Trauma."},{"issue":"3","key":"10.1016\/j.ard.2026.08.009_bib0004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/ard-2023-224728","article-title":"In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation","volume":"83","author":"Pertsinidou","year":"2024","journal-title":"Annals of the Rheumatic Diseases."},{"key":"10.1016\/j.ard.2026.08.009_bib0005","first-page":"999","article-title":"Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis","volume":"42","author":"Mart\u00ednez-Feito","year":"2024","journal-title":"Clin Exp Rheumatol."},{"issue":"9","key":"10.1016\/j.ard.2026.08.009_bib0006","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology."},{"issue":"6","key":"10.1016\/j.ard.2026.08.009_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/annrheumdis-2012-201517","article-title":"Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity","volume":"72","author":"Aletaha","year":"2013","journal-title":"Annals of the rheumatic diseases."},{"issue":"3","key":"10.1016\/j.ard.2026.08.009_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002817","article-title":"Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis","volume":"9","author":"Motta","year":"2023","journal-title":"RMD open."},{"issue":"2","key":"10.1016\/j.ard.2026.08.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089442","article-title":"The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNF\u03b1 Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis","volume":"9","author":"Lv","year":"2014","journal-title":"PLOS ONE."},{"issue":"1","key":"10.1016\/j.ard.2026.08.009_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-022-01821-0","article-title":"Ozoralizumab: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.ard.2026.08.009_bib0011","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/rheumatology\/keae435","article-title":"Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis","volume":"63","author":"Smolen","year":"2024","journal-title":"Rheumatology."},{"key":"10.1016\/j.ard.2026.08.009_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1401-2","volume":"19","author":"Takeuchi","year":"2017","journal-title":"Arthritis research & therapy."},{"key":"10.1016\/j.ard.2026.08.009_bib0013","series-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","author":"Akers","year":"2009"},{"key":"10.1016\/j.ard.2026.08.009_bib0014","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.ard.2026.08.009_bib0015","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"issue":"9","key":"10.1016\/j.ard.2026.08.009_bib0016","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"10.1016\/j.ard.2026.08.009_bib0017","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/acr.80009","article-title":"Impact of dual rheumatoid factor and anti-citrullinated protein antibody seropositive, single seropositive, and seronegative rheumatoid arthritis on outcomes","volume":"78","author":"Brooks","year":"2026","journal-title":"Arthritis Care."},{"issue":"7","key":"10.1016\/j.ard.2026.08.009_bib0018","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00296-021-05086-w","article-title":"Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study","volume":"42","author":"Nakayama","year":"2022","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.ard.2026.08.009_bib0019","unstructured":"Knowledge N. Screening model [nested knowledge]. [updated 2024; cited 2026 Jan 26]. Available from https:\/\/about.nested-knowledge.com\/docs\/#testing_out_the_model"},{"key":"10.1016\/j.ard.2026.08.009_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019","journal-title":"Cochrane handbook for systematic reviews of interventions"},{"key":"10.1016\/j.ard.2026.08.009_bib0021","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"10.1016\/j.ard.2026.08.009_bib0022","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2024-eular.2568","article-title":"POS0722 Purified monoclonal rheumatoid factors bind Fc containing TNF inhibitors in vitro but not the Fc-free TNF inhibitor, Certolizumab Pegol","volume":"83","author":"Bidgood","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.08.009_bib0023","unstructured":"Kanda-Satoh. Does rheumatoid factor level affect the pharmacodynamics of disease-modifying antirheumatic drugs and the efficacy of tumour necrosis factor inhibitors with different molecular structures? In vitro and clinical findings from the FIRST Registry. 2024."},{"issue":"6","key":"10.1016\/j.ard.2026.08.009_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217624","article-title":"Immunoglobulin G structure and rheumatoid factor epitopes","volume":"14","author":"Maibom-Thomsen","year":"2019","journal-title":"PLoS One."},{"key":"10.1016\/j.ard.2026.08.009_bib0025","series-title":"Presented at: 69th Annual Meeting of the Japan College of Rheumatology","article-title":"A novel TNF inhibitor ozoralizumab is unaffected by rheumatoid factor in the recycling mechanism via neonatal Fc receptor","author":"Fujii","year":"2025"},{"issue":"10","key":"10.1016\/j.ard.2026.08.009_bib0026","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2003.014647","article-title":"Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF\u03b1 therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement","volume":"63","author":"Alessandri","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.08.009_bib0027","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00296-004-0571-9","article-title":"Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment","volume":"26","author":"Caramaschi","year":"2005","journal-title":"Rheumatol Int."},{"issue":"2","key":"10.1016\/j.ard.2026.08.009_bib0028","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/ard.2004.023523","article-title":"Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis","volume":"64","author":"De Rycke","year":"2005","journal-title":"Ann Rheum Dis.."},{"issue":"suppl","key":"10.1016\/j.ard.2026.08.009_bib0029","first-page":"S167","article-title":"W43-5: usefulness of certolizumab pegol useful rheumatoid arthritis with high rheumatoid factor","volume":"34","author":"Yamano","year":"2024","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2026.08.009_bib0030","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.ard.2025.06.1633","article-title":"ABS1004 Unraveling the influence of rheumatoid factor on RA treatment success","volume":"84","author":"Ju\u00e1rez","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ard.2026.08.009_bib0031","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40744-025-00769-3","article-title":"Influence of rheumatoid factors on the efficacy of TNF inhibitor therapy in patients with rheumatoid arthritis","volume":"12","author":"Nagayasu","year":"2025","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.ard.2026.08.009_bib0032","series-title":"Paper presented at: The 69th Japan College of Rheumatology","article-title":"Treatment response in patients with rheumatoid arthritis treated certolizumab pegol based on rheumatoid factor levels","author":"Fujibayashi","year":"2025"},{"key":"10.1016\/j.ard.2026.08.009_bib0033","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/annrheumdis-2024-eular.2883","article-title":"Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase 3b realistic trial","volume":"83","author":"Smolen","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"10.1016\/j.ard.2026.08.009_bib0034","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1093\/rheumatology\/keaf171","article-title":"Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial","volume":"64","author":"Watanabe","year":"2025","journal-title":"Rheumatology."},{"key":"10.1016\/j.ard.2026.08.009_bib0035","first-page":"suppl 9","article-title":"Certolizumab inhibits radiographic progression even in RA patients with high rheumatoid factor levels: a pooled, post-hoc analysis of two phase 3 trials","volume":"76","author":"Smolen","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.ard.2026.08.009_bib0036","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/1756-185X.14699","article-title":"Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: post-hoc analysis of clinical trials","volume":"26","author":"Tanaka","year":"2023","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.ard.2026.08.009_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1461396","article-title":"Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients","volume":"11","author":"Plasencia-Rodr\u00edguez","year":"2024","journal-title":"Front Med."},{"issue":"Suppl 9","key":"10.1016\/j.ard.2026.08.009_bib0038","first-page":"76","article-title":"Fragment crystallizable (Fc)-free certolizumab pegol is not bound by rheumatoid factors, while fc containing biological DMARDsAre, driving immunecomplex formation and cellular clearance","volume":"76","author":"Bidgood","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.ard.2026.08.009_bib0039","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1084\/jem.108.1.105","article-title":"Interaction of the rheumatoid factor with antigen-antibody complexes and aggregated gamma globulin","volume":"108","author":"Edelman","year":"1958","journal-title":"J Exp Med."},{"issue":"4","key":"10.1016\/j.ard.2026.08.009_bib0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs."},{"issue":"9","key":"10.1016\/j.ard.2026.08.009_bib0041","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/ard-2023-225271","article-title":"Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry","volume":"83","author":"Hern\u00e1ndez-Cruz","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.08.009_bib0042","article-title":"Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience","volume":"2011","author":"Singh","year":"2011","journal-title":"Arthritis."},{"issue":"2","key":"10.1016\/j.ard.2026.08.009_bib0043","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology."},{"issue":"1","key":"10.1016\/j.ard.2026.08.009_bib0044","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.08.009_bib0045","series-title":"Paper presented at: ACR Convergence 2025","article-title":"Rheumatoid factors (RFs) in RA patient sera do not bind to Fc-free certolizumab pegol, but do bind to Fc-containing anti-TNF-\u03b1 biological DMARDs, driving immune complex formation and cellular clearance [abstract]","author":"Hopkin","year":"2025"},{"key":"10.1016\/j.ard.2026.08.009_bib0046","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","article-title":"Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer","volume":"116","author":"Porter","year":"2016","journal-title":"Reprod Immunol."},{"issue":"5","key":"10.1016\/j.ard.2026.08.009_bib0047","first-page":"689","article-title":"Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis","volume":"56","author":"Choy","year":"2017","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.ard.2026.08.009_bib0048","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"9410","key":"10.1016\/j.ard.2026.08.009_bib0049","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.ard.2026.08.009_bib0050","first-page":"409","article-title":"Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis","volume":"21","author":"Buckley","year":"2015","journal-title":"J Manag Care Spec Pharm."},{"issue":"4","key":"10.1016\/j.ard.2026.08.009_bib0051","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","article-title":"Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Soliman","year":"2011","journal-title":"Ann Rheum Dis."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:15:29Z","timestamp":1793448929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726004942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"alternative-id":["S0003496726004942"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.08.009","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}